Terms: = Ovarian cancer AND MITF, WS2A, ENSG00000187098, 4286 AND Treatment
4 results:
1. Pre-treatment sarcopenic assessments as a prognostic factor for gynaecology cancer outcomes: systematic review and meta-analysis.
Sutton EH; Plyta M; Fragkos K; Di Caro S
Eur J Clin Nutr; 2022 Nov; 76(11):1513-1527. PubMed ID: 35194194
[TBL] [Abstract] [Full Text] [Related]
2. Integrative microRNA and gene expression analysis identifies new epigenetically regulated microRNAs mediating taxane resistance in ovarian cancer.
Hassan MK; Waly AA; Elsayed W; Keshk S; Allam WR; El-Khamisy SF
Sci Rep; 2021 Jan; 11(1):562. PubMed ID: 33436648
[TBL] [Abstract] [Full Text] [Related]
3. mitf-Mdel, a novel melanocyte/melanoma-specific isoform of microphthalmia-associated transcription factor-M, as a candidate biomarker for melanoma.
Wang Y; Radfar S; Liu S; Riker AI; Khong HT
BMC Med; 2010 Feb; 8():14. PubMed ID: 20163701
[TBL] [Abstract] [Full Text] [Related]
4. Malignant melanoma involving the ovary: a clinicopathologic and immunohistochemical study of 23 cases.
Gupta D; Deavers MT; Silva EG; Malpica A
Am J Surg Pathol; 2004 Jun; 28(6):771-80. PubMed ID: 15166669
[TBL] [Abstract] [Full Text] [Related]
